New Developments on the Treatment of Liver Fibrosis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Liver fibrosis results from many chronic injuries and often progresses to cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Liver transplantation is the only treatment available for patients with advanced stages of liver fibrosis. Therefore, new strategies for anti-fibrotic therapy are required. Various kinds of hepatocyte damage result in inflammation, which leads to the activation of hepatic stellate cells (HSCs), which are the major source of myofibroblasts in the liver. Myofibroblasts proliferate in response to various kinds of cytokines, chemokines, and growth factors and produce extracellular matrix proteins, which forms the fibrous scar. Myofibroblasts undergo apoptosis and inactivation when the underlying causative etiologies are cleared. Here we describe our current knowledge of targeting the steps in HSC activation as therapeutic target for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Henderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3282 · Cited by 866
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Self-citationMorris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Murphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432
The α v β 1 integrin plays a critical in vivo role in tissue fibrosis
Reed, N. I., Jo, H., Chen, C., Tsujino, K., Arnold, T. D., DeGrado, W. F., & Sheppard, D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5094 · Cited by 311
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P
Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., & Gomer, R. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4035 · Cited by 230
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157
Self-citationRegulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells
Fadok, V. A., McDonald, P. P., Bratton, D. L., & Henson, P. M. (1998) · Biochemical Society Transactions · doi:10.1042/bst0260653 · Cited by 134
Cited by
Cellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis
Dobie, R., Wilson-Kanamori, J. R., Henderson, B. E. P., Smith, J. R., Matchett, K. P., Portman, J. R., Wallenborg, K., Picelli, S., Zagorska, A., Pendem, S. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.024 · Cited by 420
“Mortality rates secondary to liver cirrhosis continue to increase, with no Food and Drug Administration (FDA)- or European Medicines Agency (EMA)-approved antifibrotic treatments currently available, and liver transplantation only accessible to a select few (Friedman et al., 2018; Koyama et al., 2016; Tapper and Parik…”
BackgroundHepatic stellate cell hypertrophy is associated with metabolic liver fibrosis
Hoffmann, C., Djerir, N. E. H., Danckaert, A., Fernandes, J., Roux, P., Charrueau, C., Lachagès, A.-M., Charlotte, F., Brocheriou, I., Clément, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60615-0 · Cited by 78
Schrom, E., Huber, M., Aneja, M., Dohmen, C., Emrich, D., Geiger, J., Hasenpusch, G., Herrmann-Janson, A., Kretzschmann, V., Mykhailyk, O., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.006 · Cited by 69
Muthiah, M. D., Huang, D. Q., Zhou, L., Jumat, N. H., Choolani, M., Chan, J. K. Y., Wee, A., Lim, S. G., & Dan, Y.-Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-51189-7 · Cited by 15
Metadata
- Authors
- Koyama, Y., Xu, J., Liu, X., & Brenner, D. A.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 34
- Issue
- 5
- Pages
- 589-596
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2474457812
- Cited by
- 117
- References
- 9
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.